Psoriasis is a chronic immune-mediated disorder affecting 2–3% of the global adult population, characterized by thick, scaly plaques resulting from accelerated keratinocyte proliferation and dysfunction of the epidermis. This paper examines the pathophysiology of psoriasis, the role of T-lymphocytes and systemic inflammation in disease development, and the range of clinical manifestations including skin symptoms, psoriatic arthritis, and systemic complications. The paper discusses treatment options such as cyclosporine, acitretin, methotrexate, and phototherapy (PUVA), while emphasizing the significant impact of psoriasis on patient quality of life and the importance of early intervention to prevent serious complications.
Psoriasis is a chronic immune-mediated disorder that affects 2–3% of the human adult population globally. It is primarily characterized by thick, scaly, edematous plaques that appear on the surface of the body. The development of psoriasis originates in the basal layer of an individual's epidermis, where keratinocytes (skin cells) are normally formed. In healthy skin, keratinocytes develop in the lower layer and gradually migrate upward through the epidermis. Once they reach the outermost layers, they are shed—a process that typically occurs without noticeable symptoms.
In patients with psoriasis, however, this process becomes dysregulated. Keratinocytes are produced and migrate far more rapidly than normal; they reach the epidermal surface within approximately four days rather than the typical timeframe. Because they cannot be shed at this accelerated pace, they accumulate and form the characteristic thick plaques associated with the disorder. Additionally, the dermis beneath the epidermis—which contains lymphatic vessels, nerves, and blood vessels—becomes red and swollen (Gladman 454).
The extent of skin affected by psoriasis varies significantly among individuals. The severity of the condition is generally associated with the degree of body surface involvement. In some cases, psoriasis affects only 2% of the total body surface, while in more severe presentations, it can involve more than 20% of the skin. Regardless of the extent of involvement, psoriasis can substantially affect quality of life. According to a survey conducted by the National Psoriasis Foundation (NPF), patients with severe psoriasis often experience difficulty with everyday activities such as sitting, standing, or using their hands for extended periods. The condition typically develops early in life, with onset most common between 15 and 25 years of age (Gladman 346).
Although the pathogenesis of psoriasis cannot be fully understood with complete precision, its development is known to be associated with numerous factors. Research demonstrates that T-lymphocytes play a substantial role in psoriasis pathogenesis. The primary symptoms associated with the condition include arthritis and scaly red plaques, along with increased antigen levels in the body. Psoriasis also exhibits markers of systemic inflammation, most notably an elevation in C-reactive protein levels, indicating that the disorder has effects beyond the skin surface.
Psoriasis presents with diverse clinical manifestations affecting multiple body systems. The primary symptoms visible on the skin include redness, itching, scaling, burning sensations, and fatigue. Beyond cutaneous symptoms, the disorder affects the skeletal system as well. Approximately 30% of patients with psoriasis develop psoriatic arthritis, a complication characterized by stiffness, pain, and swelling around various joints. While psoriatic arthritis typically develops in patients with severe or moderate psoriasis, it can sometimes manifest earlier, even before significant skin involvement occurs.
Beyond skin and joint manifestations, inadequate treatment of psoriasis can result in severe impacts on an individual's life and overall functioning quality. Patients often experience substantial pain and loss of mobility. In some cases, individuals suffering from psoriasis develop secondary mental health conditions such as depression and other comorbid conditions. Additionally, those with psoriasis face a significantly elevated risk for cardiovascular diseases, underscoring the importance of comprehensive disease management and monitoring of systemic health outcomes.
Psoriasis can be treated with several pharmacological options that include cyclosporine, acitretin, methotrexate, and UV-A phototherapy (PUVA). Inadequate treatment can result in severe impacts on the life and functioning quality of an individual. Early intervention and appropriate therapeutic management are crucial to preventing serious complications and improving patient outcomes. Treatment selection should be tailored to disease severity, extent of involvement, and individual patient factors to optimize efficacy and minimize adverse effects.
"Pharmacological and phototherapy options for disease control"
You’re 87% through this paper. Sign up to read the remaining 1 section.
Sign Up Now — Instant Access Already a member? Log inAlways verify citation format against your institution’s current style guide requirements.